Marcus R. Messmer

Oncology | Hematology Oncology
333 Cottman Avenue
Philadelphia, PA 19111

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Journal: Blood cancer journal
Published: December 12, 2025

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances
Published: September 24, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances
Published: September 24, 2025

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Journal: Blood advances
Published: September 24, 2025

EBV-positive Hodgkin lymphoma with immunosuppressive microenvironment during IL-23 inhibitor therapy for psoriasis.

EBV-positive Hodgkin lymphoma with immunosuppressive microenvironment during IL-23 inhibitor therapy for psoriasis.

Journal: medRxiv : the preprint server for health sciences
Published: April 29, 2025

Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence.

Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence.

Journal: Blood neoplasia
Published: December 23, 2024

"I Missed My Other Oncologist": Established Relationships as Barriers and Facilitators to Accessing CAR-T and Autologous Transplantation.

"I Missed My Other Oncologist": Established Relationships as Barriers and Facilitators to Accessing CAR-T and Autologous Transplantation.

Journal: Cancer medicine
Published: December 16, 2024

The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.

The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.

Journal: Frontiers in immunology
Published: May 15, 2024

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 07, 2023

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

Journal: Blood advances
Published: May 16, 2023

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.

Journal: Blood advances
Published: May 03, 2023
Showing 1-12 of 19

Last Updated: 09/26/2026